← All trials
NCT05573035
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Aug 31, 2025
- Completion date
- Sep 30, 2027
- First posted
- Oct 10, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 108
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lyell Immunopharma, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.